11/21
07:30 am
pstv
Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases
Neutral
Report
Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases
11/16
02:46 pm
pstv
Plus Therapeutics, Inc. (PSTV) Q3 2024 Earnings Call Transcript [Seeking Alpha]
Low
Report
Plus Therapeutics, Inc. (PSTV) Q3 2024 Earnings Call Transcript [Seeking Alpha]
11/15
08:03 am
pstv
Plus Therapeutics, Inc. (NASDAQ: PSTV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
Medium
Report
Plus Therapeutics, Inc. (NASDAQ: PSTV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
11/15
02:34 am
pstv
Plus Therapeutics Inc (PSTV) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ... [Yahoo! Finance]
Medium
Report
Plus Therapeutics Inc (PSTV) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ... [Yahoo! Finance]
11/14
04:27 pm
pstv
Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]
Medium
Report
Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]
11/14
04:15 pm
pstv
Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Medium
Report
Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
11/6
07:30 am
pstv
Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership
Neutral
Report
Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership
11/5
07:30 am
pstv
Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024
Medium
Report
Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024
10/29
07:30 am
pstv
Plus Therapeutics Showcases Leptomeningeal Metastases Programs at the 2024 SNO Annual Meeting in Houston, Texas
Low
Report
Plus Therapeutics Showcases Leptomeningeal Metastases Programs at the 2024 SNO Annual Meeting in Houston, Texas
10/4
04:28 pm
pstv
Plus Therapeutics files for $100M mixed securities shelf [Seeking Alpha]
Medium
Report
Plus Therapeutics files for $100M mixed securities shelf [Seeking Alpha]
10/1
07:30 am
pstv
Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting
High
Report
Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting
9/18
07:30 am
pstv
Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual Meeting
High
Report
Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual Meeting
9/4
07:30 am
pstv
Plus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Low
Report
Plus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
9/3
08:04 am
pstv
Plus Therapeutics, Inc. (NASDAQ: PSTV) had its price target lowered by analysts at Ascendiant Capital Markets from $21.00 to $20.00. They now have a "buy" rating on the stock.
Medium
Report
Plus Therapeutics, Inc. (NASDAQ: PSTV) had its price target lowered by analysts at Ascendiant Capital Markets from $21.00 to $20.00. They now have a "buy" rating on the stock.